Uveal Melanoma - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Uveal Melanoma - Pipeline Review, H2 2015’, provides an overview of the Uveal Melanoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uveal Melanoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Uveal Melanoma Overview
- Therapeutics Development
- Pipeline Products for Uveal Melanoma - Overview
- Pipeline Products for Uveal Melanoma - Comparative Analysis
- Uveal Melanoma - Therapeutics under Development by Companies
- Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
- Uveal Melanoma - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Uveal Melanoma - Products under Development by Companies
- Uveal Melanoma - Products under Investigation by Universities/Institutes
- Uveal Melanoma - Companies Involved in Therapeutics Development
- Aura Biosciences, Inc.
- Celldex Therapeutics, Inc.
- Eli Lilly and Company
- GlaxoSmithKline Plc
- Immunocore Limited
- Navigen Pharmaceuticals, Inc.
- Novartis AG
- PEP-Therapy SAS
- Pfizer Inc.
- Spectrum Pharmaceuticals, Inc.
- Uveal Melanoma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- AU-011 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- axitinib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- crizotinib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Dendritic Cell Therapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DPTPEP-1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- emibetuzumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- glembatumumab vedotin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IMCgp100 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- KCN-1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- merestinib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NAV-2729 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- nutlin-3 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- pasireotide LAR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- sunitinib malate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- trametinib dimethyl sulfoxide + uprosertib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vaccine 2 for Melanoma - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- vincristine sulfate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Uveal Melanoma - Recent Pipeline Updates
- Uveal Melanoma - Dormant Projects
- Uveal Melanoma - Discontinued Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Uveal Melanoma, H2 2015
- Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Investigation by Universities/Institutes, H2 2015
- Uveal Melanoma - Pipeline by Aura Biosciences, Inc., H2 2015
- Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2015
- Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2015
- Uveal Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2015
- Uveal Melanoma - Pipeline by Immunocore Limited, H2 2015
- Uveal Melanoma - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015
- Uveal Melanoma - Pipeline by Novartis AG, H2 2015
- Uveal Melanoma - Pipeline by PEP-Therapy SAS, H2 2015
- Uveal Melanoma - Pipeline by Pfizer Inc., H2 2015
- Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
- Assessment by Monotherapy Products, H2 2015
- Assessment by Combination Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Uveal Melanoma Therapeutics - Recent Pipeline Updates, H2 2015
- Uveal Melanoma - Dormant Projects, H2 2015
- Uveal Melanoma - Discontinued Products, H2 2015
- List of Figures
- Number of Products under Development for Uveal Melanoma, H2 2015
- Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Products, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook